NKX2.2, a homeodomain transcription factor involved in neuroendocrine/glial differentiation and a downstream target of EWSR1-FLI1, is recognized as a specific molecular marker in the diagnosis of ES, and its combination with CD99 makes this test highly specific (24). This evidence concerns the gene CD99 and Ewing sarcoma.